164 related articles for article (PubMed ID: 18676347)
1. PTH, FGF-23 and early CKD.
Rodriguez M; Felsenfeld AJ
Nephrol Dial Transplant; 2008 Nov; 23(11):3391-3. PubMed ID: 18676347
[No Abstract] [Full Text] [Related]
2. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
[TBL] [Abstract][Full Text] [Related]
3. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.
Isakova T; Gutierrez O; Shah A; Castaldo L; Holmes J; Lee H; Wolf M
J Am Soc Nephrol; 2008 Mar; 19(3):615-23. PubMed ID: 18216315
[TBL] [Abstract][Full Text] [Related]
4. Regulation of fibroblast growth factor-23 in chronic kidney disease.
Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P
J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479
[TBL] [Abstract][Full Text] [Related]
6. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
Damasiewicz MJ; Toussaint ND; Polkinghorne KR
Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
[TBL] [Abstract][Full Text] [Related]
8. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
[TBL] [Abstract][Full Text] [Related]
9. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
[TBL] [Abstract][Full Text] [Related]
10. FGF23 and mineral metabolism, implications in CKD-MBD.
Rodríguez M; López I; Muñoz J; Aguilera-Tejero E; Almaden Y
Nefrologia; 2012 May; 32(3):275-8. PubMed ID: 22592418
[No Abstract] [Full Text] [Related]
11. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
Yaginuma T; Yamamoto H
Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiology of secondary hyperparathyroidism: the role of FGF23 and Klotho].
Mazzaferro S; Pasquali M; Tartaglione L; Rotondi S; Pirrò G
G Ital Nefrol; 2009; 26 Suppl 49():S11-7. PubMed ID: 19941273
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy.
Westerberg PA; Ljunggren O; Larsson TE; Wadström J; Linde T
Nephrol Dial Transplant; 2010 Dec; 25(12):4068-71. PubMed ID: 20525976
[TBL] [Abstract][Full Text] [Related]
14. Regulation of parathyroid function in chronic kidney disease (CKD).
Fukagawa M; Nakanishi S; Fujii H; Hamada Y; Abe T
Clin Exp Nephrol; 2006 Sep; 10(3):175-9. PubMed ID: 17009074
[TBL] [Abstract][Full Text] [Related]
15. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
Akiba T
Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.
Kanbay M; Nicoleta M; Selcoki Y; Ikizek M; Aydin M; Eryonucu B; Duranay M; Akcay A; Armutcu F; Covic A
Clin J Am Soc Nephrol; 2010 Oct; 5(10):1780-6. PubMed ID: 20576822
[TBL] [Abstract][Full Text] [Related]
17. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease.
Wahl P; Xie H; Scialla J; Anderson CA; Bellovich K; Brecklin C; Chen J; Feldman H; Gutierrez OM; Lash J; Leonard MB; Negrea L; Rosas SE; Anderson AH; Townsend RR; Wolf M; Isakova T;
Diabetes Care; 2012 May; 35(5):994-1001. PubMed ID: 22446176
[TBL] [Abstract][Full Text] [Related]
18. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
Gal-Moscovici A; Sprague SM; Hutchison AJ; Shah N; Piraino B; Cunningham J
Semin Dial; 2007; 20(1):24-32. PubMed ID: 17244115
[No Abstract] [Full Text] [Related]
19. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
Yano S
Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
[TBL] [Abstract][Full Text] [Related]
20. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.
Kooienga L; Fried L; Scragg R; Kendrick J; Smits G; Chonchol M
Am J Kidney Dis; 2009 Mar; 53(3):408-16. PubMed ID: 19185400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
